Title: 2025-2026 Regular Session HR 302 PN 2261 Bill Text (HTM)
Official Title: 
Number of Sections: 1
Source: versions - Printer's No. PN2261
Media Type: text/html

================================================================================

Section 1:
2025-2026 Regular Session HR 302 PN 2261 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 2261 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.302 Session of 2025 INTRODUCED BY SCOTT, GIRAL, HARKINS, McNEILL, WAXMAN, HILL-EVANS, SANCHEZ, CEPEDA-FREYTIZ, MAYES, HOHENSTEIN, COOPER AND D. WILLIAMS, SEPTEMBER 3, 2025 REFERRED TO COMMITTEE ON HEALTH, SEPTEMBER 4, 2025 A RESOLUTIONEnsuring greater access to sickle cell disease treatments and designating the Department of Health to conduct a comprehensive and coordinated data collection effort to better understand and quantify the scope and impact of sickle cell disease on patients, communities and states throughout the United States.WHEREAS, Sickle cell disease is a severe, life-shortening and inherited blood disorder that predominantly impacts people of color, particularly African Americans; andWHEREAS, Sickle cell disease is a disease in which a person's body produces abnormally shaped red blood cells that resemble a crescent or sickle; andWHEREAS, Sickle cell disease typically first appears in children around six months of age; andWHEREAS, Symptoms of sickle cell disease may include anemia, pain, swelling of hands and feet, frequent infections, delayed growth or puberty and vision problems; andWHEREAS, According to the Department of Health, an estimated 3,870 Pennsylvanians were reported living with sickle cell 12345678910111213141516171819 disease in 2019-2020; andWHEREAS, The exact number of people with sickle cell disease nationwide is still unknown, though the Centers for Disease Control and Prevention estimates that sickle cell disease affects more than 100,000 Americans; andWHEREAS, Sickle cell disease occurs in approximately 1 out of every 365 Black or African-American births nationwide; andWHEREAS, Individuals living with sickle cell disease encounter barriers to obtaining quality care, such as limited geographic access, financial and socioeconomic barriers, specialist availability, transportation needs, translation services and social factors, such as stigma, bias and lack of public awareness; andWHEREAS, Due to new treatments, individuals with sickle cell disease now have a longer life expectancy, improved quality of life and survival rates past 50 years of age; andWHEREAS, However, there is a need for more comprehensive and coordinated data collection efforts to better understand and quantify the scope and impact of sickle cell disease; andWHEREAS, Further, there is a need for states to provide open access to therapies that treat sickle cell disease, particularly innovative therapies that have been approved in recent years to treat the underlying cause of the disease; andWHEREAS, Scientific and medical research advances need to be coupled with health care delivery and payment policies to ensure universal access to innovative products, particularly for Medicaid beneficiaries; andWHEREAS, Efforts should focus on the identification and the promotion of affordable interventions, including community education, training of health professionals and newborn 20250HR0302PN2261 - 2 - 123456789101112131415161718192021222324252627282930 screening for early diagnosis of sickle cell disease; andWHEREAS, Involving other potential stakeholders, such as organizations and other national and international health-related agencies, would significantly contribute to efforts relating to advocacy, technology transfer and capacity building; therefore be itRESOLVED, That the House of Representatives ensure greater access to sickle cell disease treatments and designate the Department of Health to conduct a comprehensive and coordinated data collection effort to better understand and quantify the scope and impact of sickle cell disease on patients, communities and states throughout the United States; and be it furtherRESOLVED, That the House of Representatives and members of the Legislative Black Caucus urge Federal policymakers to ensure that individuals with sickle cell disease have access to all medications and forms of treatment for the disease, including services for enrollees who are diagnosed with the disease and who are eligible for covered services under Medicare and Medicaid programs, and to ensure that new and effective treatments are developed for sickle cell disease.20250HR0302PN2261 - 3 - 1234567891011121314151617181920


================================================================================

Raw Text:
2025-2026 Regular Session HR 302 PN 2261 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 2261 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.302 Session of 2025 INTRODUCED BY SCOTT, GIRAL, HARKINS, McNEILL, WAXMAN, HILL-EVANS, SANCHEZ, CEPEDA-FREYTIZ, MAYES, HOHENSTEIN, COOPER AND D. WILLIAMS, SEPTEMBER 3, 2025 REFERRED TO COMMITTEE ON HEALTH, SEPTEMBER 4, 2025 A RESOLUTIONEnsuring greater access to sickle cell disease treatments and designating the Department of Health to conduct a comprehensive and coordinated data collection effort to better understand and quantify the scope and impact of sickle cell disease on patients, communities and states throughout the United States.WHEREAS, Sickle cell disease is a severe, life-shortening and inherited blood disorder that predominantly impacts people of color, particularly African Americans; andWHEREAS, Sickle cell disease is a disease in which a person's body produces abnormally shaped red blood cells that resemble a crescent or sickle; andWHEREAS, Sickle cell disease typically first appears in children around six months of age; andWHEREAS, Symptoms of sickle cell disease may include anemia, pain, swelling of hands and feet, frequent infections, delayed growth or puberty and vision problems; andWHEREAS, According to the Department of Health, an estimated 3,870 Pennsylvanians were reported living with sickle cell 12345678910111213141516171819 disease in 2019-2020; andWHEREAS, The exact number of people with sickle cell disease nationwide is still unknown, though the Centers for Disease Control and Prevention estimates that sickle cell disease affects more than 100,000 Americans; andWHEREAS, Sickle cell disease occurs in approximately 1 out of every 365 Black or African-American births nationwide; andWHEREAS, Individuals living with sickle cell disease encounter barriers to obtaining quality care, such as limited geographic access, financial and socioeconomic barriers, specialist availability, transportation needs, translation services and social factors, such as stigma, bias and lack of public awareness; andWHEREAS, Due to new treatments, individuals with sickle cell disease now have a longer life expectancy, improved quality of life and survival rates past 50 years of age; andWHEREAS, However, there is a need for more comprehensive and coordinated data collection efforts to better understand and quantify the scope and impact of sickle cell disease; andWHEREAS, Further, there is a need for states to provide open access to therapies that treat sickle cell disease, particularly innovative therapies that have been approved in recent years to treat the underlying cause of the disease; andWHEREAS, Scientific and medical research advances need to be coupled with health care delivery and payment policies to ensure universal access to innovative products, particularly for Medicaid beneficiaries; andWHEREAS, Efforts should focus on the identification and the promotion of affordable interventions, including community education, training of health professionals and newborn 20250HR0302PN2261 - 2 - 123456789101112131415161718192021222324252627282930 screening for early diagnosis of sickle cell disease; andWHEREAS, Involving other potential stakeholders, such as organizations and other national and international health-related agencies, would significantly contribute to efforts relating to advocacy, technology transfer and capacity building; therefore be itRESOLVED, That the House of Representatives ensure greater access to sickle cell disease treatments and designate the Department of Health to conduct a comprehensive and coordinated data collection effort to better understand and quantify the scope and impact of sickle cell disease on patients, communities and states throughout the United States; and be it furtherRESOLVED, That the House of Representatives and members of the Legislative Black Caucus urge Federal policymakers to ensure that individuals with sickle cell disease have access to all medications and forms of treatment for the disease, including services for enrollees who are diagnosed with the disease and who are eligible for covered services under Medicare and Medicaid programs, and to ensure that new and effective treatments are developed for sickle cell disease.20250HR0302PN2261 - 3 - 1234567891011121314151617181920